-       Report 
   - May 2025
    -  150 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                  -       Report 
   - October 2025
    -  182 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - October 2025
    -  187 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - August 2025
     Global
   
   From       €4397EUR$4,900USD£3,859GBP 
                -       Report 
   - May 2025
    -  183 Pages 
    Global
   
   From       €4038EUR$4,500USD£3,544GBP 
                 -       Report 
   - May 2025
    -  99 Pages 
    Global
   
   From       €3500EUR$4,178USD£3,179GBP 
                -       Report 
   - September 2025
    -  205 Pages 
    Global
   
   From       €4482EUR$4,995USD£3,934GBP 
                  -       Report 
   - August 2025
    -  188 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                -       Report 
   - August 2025
    -  90 Pages 
    Global
   
   From       €3500EUR$4,178USD£3,179GBP 
                -       Report 
   - May 2025
    -  100 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                -       Report 
   - May 2025
    -  100 Pages 
    Global
   
   From       €5339EUR$5,950USD£4,686GBP 
                  -       Report 
   - August 2025
    -  184 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  197 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  186 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  192 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  197 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  183 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  190 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  197 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
                  -       Report 
   - August 2025
    -  186 Pages 
    Global
   
   From       €3181EUR$3,545USD£2,792GBP 
      €3535EUR$3,939USD£3,102GBP 
             
          The Psoriasis Drugs market is a segment of the pharmaceutical industry that focuses on the development and sale of drugs used to treat psoriasis, a chronic skin condition. Psoriasis is characterized by red, scaly patches on the skin, and can cause itching, burning, and pain. Psoriasis drugs are designed to reduce inflammation, reduce the rate of skin cell growth, and reduce the severity of symptoms.
The Psoriasis Drugs market is highly competitive, with many companies offering a variety of    treatments. Some of the major players in the market include AbbVie, Amgen, Celgene, Janssen, and Novartis. These companies offer a range of treatments, including topical creams, oral medications, and biologic drugs. Other companies in the market include Sun Pharmaceuticals, Glenmark Pharmaceuticals, and Lupin Pharmaceuticals. Show Less   Read more